MULTIPLE MYELOMA

This study tests whether extra COVID-19 vaccine doses can improve protection for people with weakened immune systems, including those with HIV, organ transplants, or blood cancers. About 960 participants will receive different booster schedules to see which works best. The goal i…

This study looks at whether the PCV13 pneumonia vaccine is safe and effective for people with multiple myeloma, a blood cancer that raises infection risk. About 100 participants will get either one or two doses of the vaccine. Researchers will check how well the immune system res…

This study gives venetoclax to 165 people with blood cancers like leukemia and lymphoma who already benefited from the drug in earlier studies. The main goal is to track side effects and see how safe the drug is over a longer period. Participants must have tolerated the drug well…

This early-phase study tests a new drug called talquetamab combined with other cancer treatments for people with multiple myeloma, a type of blood cancer. The main goal is to check safety and find the best doses. About 166 participants will be enrolled.

This study tests a combination of two immune-boosting antibodies, talquetamab and teclistamab, in people with multiple myeloma that has returned or stopped responding to treatment. The goal is to find the safest and most effective dose and to see how well the drugs shrink tumors.…

This study tests whether a three-drug combination (isatuximab, lenalidomide, and dexamethasone) can eliminate tiny amounts of multiple myeloma that remain in the bone marrow after a stem cell transplant. It enrolls 30 adults whose cancer is still detectable by a sensitive test. T…

This study tests two drug combinations—iberdomide plus dexamethasone, with or without daratumumab—in 140 older adults (65+) newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. The goal is to see how well these treatments control the cancer and h…

This study tests whether a combination of three drugs (lenalidomide, bortezomib, and dexamethasone) works as well as or better than high-dose chemotherapy with a stem cell transplant for people with newly diagnosed multiple myeloma. The trial includes 729 patients up to age 65. T…

This study tests an experimental radioactive drug called iopofosine I 131 in people with certain blood cancers (like Waldenstrom macroglobulinemia, multiple myeloma, and lymphoma) that have come back or not responded to standard treatments. The drug is designed to target and kill…

This study tests two different drug combinations in people with multiple myeloma that has come back or stopped responding to treatment. About 117 participants will receive either selinexor plus pomalidomide and dexamethasone or elotuzumab plus pomalidomide and dexamethasone. The …

This study tests two targeted drugs, dabrafenib and trametinib, in 30 people with multiple myeloma that has returned or not responded to treatment. The goal is to see if these drugs can shrink the cancer. Participants must have measurable signs of myeloma. The study is in an earl…

This study tests a personalized treatment plan using the drug daratumumab for adults aged 65 and older who have newly diagnosed multiple myeloma and cannot tolerate high-dose chemotherapy. The goal is to see how well the treatment controls the disease by measuring tumor shrinkage…

This study tests whether a combination of two drugs (daratumumab and lenalidomide) works better than the current standard treatment for frail older adults with newly diagnosed multiple myeloma who cannot have a stem cell transplant. About 294 participants will receive either the …

This Phase 3 trial compares two drug combinations for people with multiple myeloma that has come back or stopped responding to treatment. About 494 participants receive either a new drug (belantamab mafodotin) plus standard drugs, or another approved combination. The goal is to s…

This study tests an experimental drug called etentamig (ABBV-383) in about 55 adults with multiple myeloma that has returned or not improved after prior treatments. The drug is given as a shot under the skin or through an IV to see if it can control the cancer. The main goals are…

This phase 3 trial compares two chemotherapy combinations (melphalan and prednisone with either thalidomide or lenalidomide) in 306 newly diagnosed multiple myeloma patients who cannot undergo high-dose therapy. The study aims to see which combination better delays cancer progres…

This study tests a new treatment plan for people newly diagnosed with multiple myeloma, a type of blood cancer. It combines several drugs and a stem cell transplant to see if it works better than previous treatments, especially for those with certain chromosome changes. The goal …

This study tests a new drug called elranatamab in people with multiple myeloma, a type of blood cancer, that has not responded to at least three prior treatments. The drug works by helping the body's immune cells attack the cancer cells. The main goal is to see how many patients …

This early-stage study tests a new treatment called P-BCMA-ALLO1 for people with multiple myeloma that has come back or stopped responding to standard therapies. The treatment uses specially engineered immune cells (CAR-T cells) from a healthy donor to attack cancer cells. The ma…

This study tests different sequences of advanced therapies (Cilta-cel, Tal-D, and Tec-D) after initial treatment in 43 people with newly diagnosed, standard-risk multiple myeloma. The goal is to see if these combinations can lead to a deep, lasting remission that might be a cure.…

This early-phase study tests a new drug called sotatercept (ACE-011) combined with two standard treatments (lenalidomide or pomalidomide plus dexamethasone) in 33 adults with multiple myeloma that has returned or not responded to prior therapy. The main goal is to find the safest…

This study tested a new treatment called BCMA CAR-T cell therapy for people with a high-risk type of multiple myeloma who still had signs of cancer after their first stem cell transplant. The goal was to see if the therapy could safely clear the remaining cancer cells. The study …

This study tests a combination of two treatments, ciltacabtagene autoleucel (a cell therapy) and talquetamab (a targeted drug), in people with high-risk multiple myeloma. The main goal is to check safety, and it also looks at how well the cancer responds. About 11 participants wh…

This study is for people with multiple myeloma that has come back or stopped responding to at least three prior treatments. It tests a combination of two drugs: belantamab mafodotin and nirogacestat. The goal is to find the safest dose and see how well the combination controls th…

This study compares a new two-drug combination (teclistamab plus daratumumab) against two standard three-drug regimens for people whose multiple myeloma has returned or stopped responding to prior therapy. About 587 participants will be randomly assigned to receive either the new…

This study tests whether adding daratumumab, a newer targeted therapy, to the standard Total Therapy approach helps people with newly diagnosed multiple myeloma live longer without their cancer getting worse. About 50 participants will receive the drug at different times during t…

This study tests a drug called selinexor combined with other cancer medicines (carfilzomib, daratumumab, or pomalidomide) in people with multiple myeloma whose current treatment has stopped working. About 96 adults will join, and researchers will measure how many patients see the…

This study tests a new four-drug combination (Dara-SVD) for people with high-risk newly diagnosed multiple myeloma. It compares this experimental treatment to the current standard therapy. The goal is to see if the new combo leads to deeper cancer remission. About 70 participants…

This study tests a combination of two drugs, belantamab mafodotin and isatuximab, in people with multiple myeloma that has come back or stopped responding to at least three prior treatments. The goal is to find a safe dose and see how well the combo shrinks tumors. About 30 adult…

This study tests whether a combination of three drugs (daratumumab, carfilzomib, and dexamethasone, called DKd) can prevent or slow down the progression of smoldering multiple myeloma into active disease. It includes 14 adults with high-risk smoldering myeloma. Participants recei…

This study tests whether adding nivolumab (an immunotherapy drug) can improve the response in people with relapsed/refractory multiple myeloma who did not get a complete response from ide-cel CAR-T therapy. The trial enrolled 1 adult participant with measurable disease and good p…

This early-stage study is testing a new drug called HPN217 in about 100 people whose multiple myeloma has returned or stopped responding to standard treatments. The main goal is to check the drug's safety and find the best dose. Researchers will also measure how the drug moves th…

This study tests a drug called cevostamab in 90 people whose multiple myeloma has returned or stopped responding to other treatments. The drug is given through a vein and aims to shrink or control the cancer. The study checks how well it works and what side effects occur.

This study tests a less intense version of a standard four-drug combination (Dara-RVd) for people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal is to see if giving one of the drugs (bortezomib) once a week instead of twice a week stil…

This study tests a drug called selinexor combined with other standard treatments for multiple myeloma, a type of blood cancer. It includes 300 patients whose cancer has come back or is hard to treat, as well as some newly diagnosed patients. The goal is to find the best doses and…

This early-phase study tests a combination of four drugs (cyclophosphamide, pomalidomide, dexamethasone, and daratumumab) in 16 people with multiple myeloma that has returned or stopped responding to prior treatments. The main goal is to find the safest dose of the drug pomalidom…

This study follows 75 adults with multiple myeloma that has come back or not responded to treatment. They are taking a combination of selinexor, bortezomib, and dexamethasone as part of their regular care. The goal is to see how this treatment affects their quality of life and ho…

This phase 3 study tests whether a new drug combination (belantamab mafodotin plus bortezomib and dexamethasone) works better than a standard combination (daratumumab plus bortezomib and dexamethasone) for people with multiple myeloma that has come back or stopped responding to t…

This phase 3 study tests whether a single infusion of cilta-cel (a CAR-T cell therapy) after initial chemotherapy can delay cancer progression better than standard long-term maintenance therapy in people newly diagnosed with multiple myeloma who cannot have a stem cell transplant…

This study compares two treatment regimens (KRd and VRd) in 250 adults newly diagnosed with multiple myeloma. The goal is to see which combination better delays cancer progression. Participants receive one of the two drug combos, and researchers track how long they live without t…

This program provides early access to teclistamab for people with relapsed or refractory multiple myeloma who have run out of standard treatment options. Participants must have tried all available therapies, including proteasome inhibitors, IMiDs, and anti-CD38 antibodies. The go…

This study tests a drug called belantamab mafodotin, alone or with other cancer drugs, in people whose multiple myeloma has returned or stopped responding to at least three prior treatments. The drug targets a protein on myeloma cells to deliver a toxin directly. The trial aims t…

This phase 3 study tests whether adding the drug isatuximab to a standard two-drug regimen (lenalidomide and dexamethasone) works better with or without a third drug (bortezomib) for newly diagnosed multiple myeloma. The study includes 270 non-frail patients aged 65 to 79 who are…

This study tests a combination of three drugs (ixazomib, pomalidomide, and dexamethasone) in people whose multiple myeloma has returned or stopped responding to treatment. The goal is to see if this new mix can control the cancer and how safe it is. About 52 adults with relapsed …

This study tests a three-drug combination (ixazomib, lenalidomide, and dexamethasone) given after a stem cell transplant to people with multiple myeloma. The goal is to see if this treatment can keep the cancer away longer. After four cycles, participants receive one of two maint…

This study looks at 69 adults with multiple myeloma who have had a stem cell transplant. It compares taking one maintenance drug versus two drugs together to see which better keeps the cancer from coming back. The goal is to improve long-term control of the disease.

This study tests a combination of four drugs (carfilzomib, lenalidomide, dexamethasone, and isatuximab) in 50 adults with newly diagnosed multiple myeloma who are eligible for a stem cell transplant. The goal is to see how many patients achieve a complete response after four trea…

This long-term follow-up study tracks about 100 people with multiple myeloma who previously received the experimental cell therapy P-BCMA-101. The goal is to check for delayed side effects and see how well the treatment controls the cancer over up to 15 years. Participants are mo…

This study tests a different way of giving chemotherapy to people with a high-risk form of multiple myeloma. Instead of high doses with long breaks, patients get lower doses of several drugs in shorter cycles. The goal is to keep the cancer from growing back between treatments, l…

This early-stage trial tests a new treatment called MCARH109 for people with multiple myeloma that has come back or not responded to at least three prior treatments. The therapy uses specially modified immune cells to target a protein on cancer cells. The main goal is to find the…

This study tests whether adding iberdomide (a pill) with other drugs can eliminate tiny amounts of multiple myeloma that remain after a stem cell transplant. About 80 adults who still have detectable cancer cells after transplant will receive these combinations. The goal is to ac…

This study tests a combination of four drugs—elotuzumab, pomalidomide, bortezomib, and dexamethasone—in people with multiple myeloma that has returned or stopped responding to prior treatments. The goal is to see how many patients achieve at least a partial response and to monito…

This study is for people with multiple myeloma that has come back or not responded to treatment. It tests whether a special cell therapy called Ide-Cel can be made from a patient's own immune cells and given after a stem cell transplant to help keep the cancer away. The main goal…

This phase 3 study tests whether adding daratumumab to a standard three-drug regimen (VRd) can eliminate more cancer cells in people with untreated multiple myeloma who are not eligible for a stem cell transplant. About 395 participants receive either the four-drug combination or…

This phase 3 study tests whether adding daratumumab to the standard drug lenalidomide as maintenance therapy after a stem cell transplant can help people with multiple myeloma live longer and keep the cancer from coming back. About 1,100 participants will receive either lenalidom…

This study tests whether giving palifermin and leuprolide acetate (or degarelix) can help the immune system recover more quickly after a stem cell transplant from a donor. The trial includes 82 adults with blood cancers like leukemia or lymphoma. Researchers will measure CD4+ T c…

This study looks at which treatment works best for older adults (65+) with multiple myeloma who cannot have a stem cell transplant. It compares standard drug combinations, with or without daratumumab, to see which improves survival and quality of life. The goal is to find the bes…

This study monitors the safety and effectiveness of the drug ELREXFIO (elranatamab) in 150 Korean adults with multiple myeloma that has returned or not responded to at least three prior treatments. Researchers will track side effects and how well the drug controls the cancer in e…

This study tests whether adding the drug belantamab mafodotin to a standard three-drug regimen can improve outcomes for people with multiple myeloma, a type of blood cancer. About 70 adults will receive the combination to find the best dose and see how well it controls the cancer…

This study tests a combination of four drugs (daratumumab, clarithromycin, pomalidomide, and dexamethasone) in people with multiple myeloma whose cancer returned or did not respond after prior treatment with daratumumab. The goal is to see if this combo can shrink tumors more eff…

This study tests a combination of three drugs (bortezomib, lenalidomide, and dexamethasone) in people newly diagnosed with multiple myeloma, a type of blood cancer. The goal is to find the safest dose and see how well the drugs work together to control the disease. About 68 adult…

This early-stage study tests a new drug called teclistamab combined with other cancer treatments for people with multiple myeloma, a type of blood cancer. The main goal is to check safety and find the best doses. About 140 participants who have already tried other therapies will …

This study tests a personalized approach for people newly diagnosed with multiple myeloma. After initial treatment, doctors use a sensitive test to see if any cancer cells remain. Based on the results, patients receive one of two combinations of T-cell redirecting drugs (teclista…

This study tests a new version of the chemotherapy drug melphalan (called Captisol Enabled Melphalan) in people with multiple myeloma or AL amyloidosis who are getting a stem cell transplant. The new formulation is designed to be more stable and possibly cause fewer side effects …

This study tests whether siltuximab can lessen the severity of cytokine release syndrome (CRS) and nerve-related side effects (ICANS) in 30 people receiving CAR-T cell therapy for blood cancers like lymphoma and multiple myeloma. The goal is to help patients recover faster from t…

This early-phase study tests a new treatment for people with multiple myeloma that has returned or not responded to standard therapy. The treatment uses a patient's own immune cells (T cells) that are modified in a lab to recognize and attack myeloma cells carrying a protein call…

This phase 3 study tests whether a new combination of drugs (belantamab mafodotin, bortezomib, and dexamethasone) works better than the current standard (daratumumab, bortezomib, and dexamethasone) for Japanese patients whose multiple myeloma has returned or stopped responding to…

This study tests a combination of four drugs (daratumumab, bortezomib, cyclophosphamide, and dexamethasone) in 41 people with multiple myeloma that has spread outside the bones (extramedullary disease). The goal is to see if this stronger treatment can shrink or control these har…

This study looks at how well the drug ixazomib works and what side effects it causes in adults with multiple myeloma who have already tried a different treatment (bortezomib or carfilzomib). About 72 people are taking part. The goal is to see if switching to ixazomib helps contro…

This study tests a combination of four drugs (isatuximab, pomalidomide, elotuzumab, and dexamethasone) in people with multiple myeloma that has returned or stopped responding to at least two prior treatments. The goal is to see how well this mix controls the cancer. About 28 adul…

This early-phase trial tests the safety of a new treatment for multiple myeloma, a blood cancer. The therapy uses a patient's own immune cells, modified to target a protein called BCMA on cancer cells. Up to 20 adults whose cancer has not responded to prior treatments will receiv…

This study was designed to see how the drug belantamab mafodotin works in people with relapsed or refractory multiple myeloma who also have liver problems. It aimed to compare drug levels and safety between patients with normal and impaired liver function. However, the study was …

This study tests a combination of four drugs (isatuximab, carfilzomib, lenalidomide, and dexamethasone) in 246 people newly diagnosed with high-risk multiple myeloma. The goal is to see if this treatment can make cancer undetectable in the bone marrow. Participants receive the dr…

This study tests a combination of three drugs (isatuximab, pomalidomide, and dexamethasone) at lower-than-standard doses in people with multiple myeloma that has returned or not responded to treatment. The goal is to see if this gentler approach is safe and effective for patients…

This study tests whether adding two drugs (carfilzomib and dexamethasone) to the standard maintenance drug lenalidomide after a stem-cell transplant can keep multiple myeloma from coming back longer. About 180 adults who have already had a transplant and are in at least stable di…

This phase 3 trial tests whether adding the drug isatuximab to standard treatment (lenalidomide, bortezomib, and dexamethasone) helps people with newly diagnosed multiple myeloma achieve deeper remission and live longer without the disease worsening. About 662 participants will r…

This early-stage study tests a new type of CAR-T cell therapy for people with multiple myeloma that has come back or not responded to at least three prior treatments. The therapy, UF-KURE-BCMA, is made from a simple blood draw and has a shorter manufacturing time than standard CA…

This study tests a new three-drug combination (iberdomide, elotuzumab, and dexamethasone) in people whose multiple myeloma has returned or stopped responding to treatment. The goal is to see if the combination is safe and can shrink tumors. About 37 adults with this blood cancer …

This study tests a combination of four drugs (carfilzomib, lenalidomide, vorinostat, and dexamethasone) in people with multiple myeloma that has returned or stopped responding to prior treatments. The main goals are to find a safe dose and see how well the drugs control the disea…

This study tests whether adding plinabulin to the standard drug pegfilgrastim can shorten the time white blood cells stay dangerously low after a stem cell transplant for multiple myeloma. About 17 adults aged 18-75 who are getting a transplant will receive both drugs. The goal i…

This study tested a sequence of four drugs (carfilzomib, clarithromycin, lenalidomide, and dexamethasone) in 74 adults newly diagnosed with multiple myeloma, a blood cancer. The goal was to see how well the treatment shrank the cancer and to check for side effects. Participants f…

This study follows 200 adults with multiple myeloma that has come back or stopped responding to treatment. Researchers are tracking how well the drug teclistamab works and what side effects occur when used in everyday medical practice. The main goal is to see how many patients ac…

This study compares two drug combinations for people newly diagnosed with multiple myeloma, a type of blood cancer. About 310 participants will receive either a standard three-drug regimen (carfilzomib, lenalidomide, dexamethasone) or that same regimen plus daratumumab. The goal …

This study tests whether a combination of four chemotherapy drugs can improve outcomes for people with high-risk multiple myeloma. The drugs work by killing cancer cells or stopping them from growing. The main goal is to see if the treatment can make the cancer undetectable in te…

This study tests a new treatment called CART-ddBCMA for people with multiple myeloma that has come back or not responded to at least three prior treatments. The therapy uses a patient's own immune cells, modified to target and kill cancer cells. The main goal is to see how many p…

This study tests a new drug called belantamab mafodotin against a standard combination therapy (pomalidomide plus dexamethasone) in people with multiple myeloma that has returned or stopped responding to prior treatments. About 325 adults will be randomly assigned to receive eith…

This study compares a new three-drug combination (iberdomide, daratumumab, and dexamethasone) against a standard three-drug combination (daratumumab, bortezomib, and dexamethasone) in about 939 adults whose multiple myeloma has returned or stopped responding after 1-2 prior treat…

This study compares two maintenance drugs—daratumumab and lenalidomide—for people with newly diagnosed multiple myeloma whose cancer responded well to initial treatment. The main goal is to see which drug provides better quality of life during maintenance therapy. About 95 partic…

This early-stage study tests a new drug called belantamab mafodotin combined with standard treatments (bortezomib, lenalidomide, dexamethasone) in adults newly diagnosed with multiple myeloma. The goal is to find the safest and most effective dosing schedule. About 118 participan…

This early-stage trial tests a new drug called cevostamab, alone or with other medicines, in about 126 people whose multiple myeloma has returned or stopped responding to treatment. The main goal is to find the safest dose and check for side effects. Researchers will also see if …

This study tests whether adding two drugs (lenalidomide and CC-486) to standard radiation therapy is safe and effective for people with plasmacytoma, a rare tumor of plasma cells. About 21 participants will receive the combination treatment. The goal is to see if this approach ca…

This study tests a new drug called CC-220, alone or with other medicines, in people with multiple myeloma, a type of blood cancer. The goal is to find the safest dose and see how well it controls the cancer. About 466 adults will take part, and the treatment is given as pills or …

This study tests whether adding the investigational drug isatuximab to a standard three-drug regimen can improve outcomes for people newly diagnosed with multiple myeloma, a blood cancer. About 52 adults aged up to 75 will receive the combination. The main goal is to see how many…

This study tests a combination of four drugs (daratumumab, carfilzomib, lenalidomide, and dexamethasone) in 39 adults newly diagnosed with multiple myeloma, a blood cancer. The goal is to see how many patients achieve a complete or very deep response after initial treatment. Whil…

This study tests a CAR-T cell therapy called cilta-cel in 20 people with high-risk smoldering myeloma, a pre-cancer condition. The treatment uses a patient's own immune cells, modified to attack myeloma cells, along with chemotherapy. The goal is to see if it is safe and can dela…

This study tests whether adding daratumumab to the standard maintenance drug lenalidomide can clear remaining cancer cells in people with multiple myeloma who still have signs of disease after a stem cell transplant. About 200 adults who recently had a transplant will receive eit…

This study tests a new drug called TNB-383B in people with multiple myeloma that has come back or not responded to at least three prior treatments. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The main goals are to find the safest dose…

This early-stage study tests an experimental oral drug, CFT7455, in people with non-Hodgkin's lymphoma or multiple myeloma whose cancer has returned or stopped responding to prior therapies. The main goals are to check the drug's safety and find the best dose, while also seeing i…

This study tests a new way to give the drug isatuximab as a quick shot under the skin, instead of a long IV drip, for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. The treatment combines isatuximab with three standard chemotherapy drugs (bor…

This study tests two oral drugs, mirdametinib and sirolimus, given together to people with a type of blood cancer called multiple myeloma that has come back or not responded to treatment. The cancer must have specific gene changes (KRAS or NRAS). The trial has two parts: first to…

This program gives patients with relapsed or refractory multiple myeloma access to REGN5458 before it is fully approved. It is for those who have tried other treatments and have no good options left. The goal is to control the disease and improve outcomes.

This early-phase study tests whether romosozumab, a drug used for osteoporosis, can safely improve bone health in postmenopausal women who also have multiple myeloma. Ten participants receive the drug, and researchers measure changes in bone formation and breakdown markers. The g…

This early-stage study tests combinations of daratumumab (a targeted antibody) with two other drugs (talquetamab and teclistamab) in 290 adults with multiple myeloma, a type of blood cancer. The goal is to find the safest and most effective doses and to monitor side effects. Part…

This study tests whether adding daratumumab to three standard drugs (carfilzomib, lenalidomide, and dexamethasone) is safe and effective for people newly diagnosed with multiple myeloma. About 75 participants will receive the four-drug combination. The main goal is to see how man…

This study tests whether adding lenalidomide to the standard chemotherapy (melphalan) before a stem cell transplant can improve outcomes for people with relapsed multiple myeloma. About 52 participants will receive the combination, followed by maintenance lenalidomide. The goal i…

This study tests a combination of two drugs, belantamab mafodotin and feladilimab, in about 25 adults with multiple myeloma that has come back or stopped responding to at least three prior treatments. The main goals are to check safety and find the best dose. This is not a cure, …

This study tests whether combining two approved multiple myeloma drugs, belantamab mafodotin and elotuzumab, is safe and works better together. It involves 24 adults whose cancer has returned or not responded after at least three prior treatments. The goal is to find the best dos…

This early-phase study tests whether the drug itacitinib can prevent a serious complication called cytokine release syndrome (CRS) after a stem cell transplant in people aged 60 and older with blood cancers. The study involves 32 participants who receive a 'mini' transplant from …

This study tests a combination of four drugs (daratumumab, carfilzomib, lenalidomide, and dexamethasone) as the first treatment for people newly diagnosed with multiple myeloma, a type of blood cancer. The goal is to see how well the treatment works at eliminating cancer cells an…

This study tests a drug combination including daratumumab as the first treatment for multiple myeloma patients who are not eligible for a stem cell transplant. After initial therapy, patients receive maintenance treatment until the disease returns, then they are re-treated with d…

This early-phase study tests the safety of combining TTI-622 (a drug that helps the immune system attack cancer cells) with daratumumab (a standard myeloma treatment) in people whose multiple myeloma has returned or stopped responding to prior therapies. Researchers will find the…

This study tests a new treatment called JNJ-68284528, a CAR-T cell therapy, for people with multiple myeloma, a type of blood cancer. The goal is to see if it can make cancer undetectable in the bone marrow (called minimal residual disease negative). About 210 adults who have alr…

This study tests a combination of four drugs (carfilzomib, lenalidomide, dexamethasone, and daratumumab) given before and after a stem cell transplant for people whose multiple myeloma has returned after prior treatment. The goal is to see if this intensive approach can lead to c…

This study tests whether adding a one-time CAR T-cell treatment (idecabtagene vicleucel) to standard lenalidomide maintenance therapy can better control multiple myeloma in adults who had a stem cell transplant but didn't get a full response. About 79 participants will receive ei…

This early-stage study tests a new drug called CLN-619 in 30 adults with multiple myeloma that has returned or not responded to other treatments. The drug is an antibody designed to help the immune system attack cancer cells. The main goals are to check safety and see if the drug…

This study tests a new drug, belantamab mafodotin, combined with standard therapy (VRd) in 50 adults newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal is to see if the combination is safe and effective. Patients receive several cycles of …

This early-stage study tests a new drug (XmAb24306) combined with another drug (cevostamab) in about 90 people whose multiple myeloma has returned or stopped responding after at least three prior treatments. The main goal is to check safety and find the best dose. Researchers wil…

This study tests whether adding the drug daratumumab to a standard three-drug combination (VRd) helps people with newly diagnosed multiple myeloma live longer without their cancer getting worse. About 709 patients aged 18 to 70 who are healthy enough for high-dose therapy will ta…

This study tests a combination of four drugs (belantamab mafodotin, nirogacestat, pomalidomide, and dexamethasone) in people with multiple myeloma that has come back or not responded to at least three prior treatments. The goal is to find the safest dose and see how well the comb…

This early-stage study tests a combination of three drugs—belantamab mafodotin, nirogacestat, and pomalidomide—in people whose multiple myeloma has returned or stopped responding to prior treatments. The main goal is to find the safest dose and see if the combination can slow or …

This study compares two treatments for people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. One group gets a combination of drugs (DVRd) followed by a new CAR-T cell therapy called ciltacabtagene autoleucel. The other group gets the same drugs…

This early-stage study tests an experimental pill called LOXO-338 in people with advanced blood cancers (like certain leukemias, lymphomas, and multiple myeloma) who have already tried standard treatments. The main goals are to find the safest dose and to see if the drug can shri…

This study is for people with multiple myeloma that has come back or stopped responding to at least three prior treatments. It tests a combination of four drugs: belantamab mafodotin, nirogacestat, lenalidomide, and dexamethasone. The goal is to find a safe dose and see how well …

This study tests a new treatment called cilta-cel, which uses a patient's own immune cells to fight multiple myeloma, against two standard drug combinations. The trial involves 419 adults whose cancer has returned and no longer responds to the drug lenalidomide. The main goal is …

This study tests a new drug called elranatamab (given as a shot) against the standard drug lenalidomide (taken as a pill) in people with newly diagnosed multiple myeloma who have already had a stem cell transplant. The goal is to see if elranatamab can keep the cancer from coming…

This study tests whether adding the drug BL-8040 to standard G-CSF helps collect more stem cells for transplant in people with multiple myeloma. About 180 participants were randomly assigned to receive either the combo or a placebo. The goal is to see if the combo leads to a succ…

This early-stage study tests two new drug combinations for people with multiple myeloma that has come back or stopped responding to treatment. About 59 adults will receive elranatamab (a shot under the skin) plus either carfilzomib and dexamethasone or another drug called maplirp…

This study checks if a single urine sample (spot urine) can detect myeloma proteins as well as the standard 24-hour urine collection. About 180 multiple myeloma patients starting a new treatment will provide both types of samples. If the spot test proves accurate, it could make m…

This study is testing whether a new radioactive tracer called PentixaFor can improve PET scans for people with multiple myeloma. The goal is to see if it finds cancer spots better than the standard FDG tracer, both at first diagnosis and when the disease comes back. About 45 adul…

This study tests whether a 12-week personalized exercise program (a mix of aerobic and strength training) can improve physical fitness, quality of life, and reduce fall risk in people with multiple myeloma. About 45 patients will be split into high-risk (individual training) and …

This study tests whether a drug called siltuximab can reduce symptoms like fatigue, pain, and nausea after a stem cell transplant. It includes 30 patients aged 60-75 with multiple myeloma or AL amyloidosis. The drug blocks a protein linked to inflammation, which may help patients…

This study tests a mobile app called THRIVE-M designed to help people with multiple myeloma manage stress, fatigue, and overall well-being. About 120 adults with different stages of the disease will either use the app or receive usual care. Researchers will measure changes in qua…

This study looks at whether adding acupuncture to standard pain care can reduce the need for strong opioid painkillers in people with multiple myeloma, Hodgkin disease, or non-Hodgkin lymphoma who are getting high-dose chemotherapy. About 299 adults will be randomly assigned to r…

This study looks at whether people with multiple myeloma who have no detectable cancer after a stem cell transplant and at least one year of maintenance therapy can safely stop taking their medication. Researchers will use advanced imaging and lab tests to find even the tiniest t…

This study looks for a blood test that can tell which patients with chronic lymphocytic leukemia (CLL) or multiple myeloma are at higher risk for infections. Researchers will use advanced lab methods to analyze blood samples from 150 adults. The goal is to help doctors prevent in…

This study is testing a new system that combines aging, mental health, and social needs checks for cancer patients aged 65 and older. The goal is to help doctors provide care that fits each patient's life. About 35 people with different cancers will try it during their first visi…

This study follows 357 people with multiple myeloma to see how long it takes for the disease to come back after their first treatment. Participants visit their clinic every 3 months for standard care, and researchers track signs of relapse using blood and urine tests. The goal is…

This study was designed to track immune system recovery and test a pneumococcal vaccine (PCV-21) in people receiving CAR-T therapy for blood cancers or solid tumors. Participants would have had regular clinic visits and blood tests for up to 24 months. However, the study was with…

This study was designed to find the safest dose of the chemotherapy drug bendamustine for people with multiple myeloma that had not responded to earlier treatments. It was a Phase 1 trial, meaning it was the first step in testing the drug in humans. However, the study was withdra…

This research study aims to collect tissue, blood, and other samples from 2,400 people diagnosed with breast, colon, kidney, liver, multiple myeloma, or prostate cancer at a young age. The goal is to identify genetic changes that may explain why these cancers occur early in certa…

This study follows nearly 90,000 farmers, their spouses, and children in Iowa and North Carolina to see how pesticides and other farm exposures affect their health. Researchers track who develops cancer or other diseases over many years. The goal is to find out which chemicals or…

This study looks at whether a health technology program called All4Cure helps people with multiple myeloma become more active in managing their health. About 200 participants will fill out surveys online to measure their confidence and ability to handle their care. The goal is to…

This study collects bone marrow and blood samples, along with medical history, from people with multiple myeloma, Waldenstrom macroglobulinemia, and related conditions. The samples are stored in a tissue bank for researchers to study the causes and biology of these diseases. The …

This study gathers information from 100 adults with breast, lung, gastrointestinal cancer, or multiple myeloma. Participants complete weekly online surveys about their symptoms and treatment experience for at least 12 weeks. The goal is to understand how symptoms change over time…

This study follows over 900 newly diagnosed multiple myeloma patients who cannot have a stem cell transplant. Researchers compare heart-related side effects between those taking lenalidomide and those on other standard treatments. The goal is to better understand the safety of le…

This study collects tissue and blood samples, along with medical information, from 1,600 people with various advanced cancers. The goal is to track how cancer changes over time and during treatment. Researchers hope this will help them understand why some cancers resist therapy a…

This study looks at whether a test called MMprofiler helps doctors decide on the best treatment for people with multiple myeloma, a type of blood cancer. About 250 patients who are about to start treatment will take part. The main goal is to see if the test changes what treatment…

This study tests whether analyzing the genes in a patient's tumor can help doctors choose a more effective treatment. Over 6,400 adults with advanced or hard-to-treat cancers (solid tumors, lymphoma, or myeloma) had their tumors genetically screened. Those with specific genetic c…

This study uses artificial intelligence to examine the shape and structure of individual myeloma cells from bone marrow samples. The goal is to predict certain genetic abnormalities that help doctors understand the severity of the disease. The approach aims to make testing faster…

This study does not provide any new treatment. It follows up to 1,000 adults who previously received CAR T-cell gene therapy for blood cancers like lymphoma, leukemia, or multiple myeloma. The goal is to monitor for long-term side effects, as required by regulators. Participants …

This study gathers information from 49 people with relapsed or hard-to-treat multiple myeloma and their doctors. The goal is to understand why some patients do not receive advanced cell therapies like stem cell transplants or CAR T-cell therapy. No new treatments are given; inste…

This study follows over 2,500 people with multiple myeloma to see how well approved treatments work in real-world settings, not just in controlled trials. It includes both newly diagnosed patients and those whose cancer has returned or stopped responding to therapy. The goal is t…